NFE2L2 and primary cutaneous T-cell non-Hodgkin lymphoma: Bexarotene is a rexinoid and known inhibitor of NRF2 [9, 10] and is Food and Drug Administration (FDA) approved for treatment of cutaneous T-cell lymphoma [58, 59].